Non-Invasive Prenatal Testing Industry Development and Demand Forecast Report 2030

The non-invasive prenatal testing market was valued at USD 3,987.1 million in 2021 and will grow at a rate of about 9.8% during 2021–2030, reaching USD 9,229.2 million by 2030, according to P&S Intelligence.

This development can be credited to the growing occurrence of chromosomal oddities and the increasing need for early discovery approaches. Around, 14% of stillbirths are because of inherited illnesses in pregnant women in the age group of <24 years and the count increases to 38% in women 40–45 years of age.

Of every genetic abnormality, Trisomy 21 had the highest share. Its yearly occurrence is 1 in 800 newborns, which made it the most-frequent chromosomal abnormality in the U.S. In out-and-out terms, in the U.S., more than 5,000 children are born with Trisomy 21 each year.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/non-invasive-prenatal-testing-market/report-sample

Down syndrome surges in probability as the mother ages and the majority of the time, children born with a weight less than even 1.5 kilos, which is way less than the weight of a normal baby. Furthermore, around 85% of the people born with this disorder die within a year, and only 50% live lengthier than 50 years.

Furthermore, in the U.S., around 1 in 5,000 newborns are suffering from Trisomy 18, and around 1 in 16,000 are suffering from Trisomy 13. Likewise, the occurrence of sex chromosome syndromes is around 1 in 2,000, and such conditions are brought about by several environmental reasons, such as UV radiation and smoking.

In 2021, North America had the highest revenue share, of approximately 45%, in the non-invasive prenatal testing market. This can be credited to the robust healthcare infrastructure and technological improvements in the area of diagnostics.

The U.S. is dominating North America and is also projected to develop with a CAGR of 8%, owing to the robust financial backing. Mainly because of the growing occurrence of chromosomal irregularities in the U.S. has led to an increase in the need for prenatal testing.

Since the U.S. offers progressive tests for hereditary conditions, it dominates the regional industry. Additionally, the whole-genome next-generation sequencing technology is being utilized for the purpose in Canada and the U.S. as it provides earlier and more-precise results.

In 2021, the consumables category had the largest share, of more than 60%, because of the presence of a high number of players offering consumables, such as reagents, disposables, and assay kits. The largest share is also credited to the enhancements in the tests for NIPT and a high number of sanctions to numerous assays.

Hence, the growing occurrence of chromosomal oddities and the increasing need for early discovery approaches are the major factors propelling the non-invasive prenatal testing industry. 

About P&S Intelligence

P&S Intelligence is a market research and consulting firm shaping growth strategies for enterprises with a global as well as niche presence. We specialize in both syndicate and custom market research, creating insight-laden reports that allow customers to stay ahead at every curve. Our clients range from multi-billion-dollar behemoths across industries to up and coming MSMEs and startups. Moreover, with our new offering, government and public sector advisory services, we continue to trudge ahead in our quest for revolutionizing the way economies shape themselves in these ever-changing times.